Shares of H-CYTE (OTCMKTS:HCYT) were among the biggest gainers in the previous trading session on unusual volume.
On Monday, HCYT stock went up 23% to $0.0393 with 10k shares, compared to its average volume of 40K shares. The stock has moved within a range of $0.0382 – 0.0393 after opening trade at $0.0389.
H-CYTE Names Michael Yurkowsky Chief Executive Officer
Medical biosciences firm focusing on the field of regenerate medicine, H-CYTE (OTCMKTS:HCYT) on December 6, 2021, announced naming Michael Yurkowsky as the Chief Executive Officer starting immediately.
Yurkowsky has over two and half decades of experience in financial services to H-CYTE, serving currently on the board of directors since 2019. He also serves as Chairman and President of Deverra Therapeutics, a clinical-stage biotech developing allogeneic cell therapies.
Through the family office, YP Holdings has invested in more than 50 private and public companies in the Life Sciences sector.
Michael Yurkowsky said that he is looking forward on assuming the role at the company as the long-time participation as well as financial industry experience makes him most suitable on leading the company forward. The incoming CEO will ensure an aggressive strategy, intending to acquire targeted assets
Yurkowsky is looking to focus on augmenting shareholder value through lowering cash burn as well as broadening the product portfolio.
Ray Monteleone, Chairman of H-CYTE said that the company is looking forward on working with Michael on the new role and would like to express gratitude to Tanya Rhodes, who played a key role for the firm as Interim CEO.
H-CYTE’s mission is to be a leader in cellular therapeutics, next-generation treatment of chronic health conditions to improve patient lives.